Life science company, Proteomics International Laboratories Ltd (ASX:PIQ) (PILL), will utilise its proprietary disruptive technology platform to assess potential new painkilling and antibiotic drug compounds.
Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market. The peptide therapeutics market estimated value is $17 billion.
A peptide is a small protein built from amino acids – one of the building blocks of life – and they occur naturally in the body.
The program is low cost, yet has the potential deliver major end returns.
Specific test details
PILL is specifically targeting the discovery of new analgesic (painkilling) and antibiotics compounds and will test 50 - 100 venoms in the program.
The program is low cost to PILL, with no additional costs incurred apart from the sourcing of venom samples, and has the potential deliver highly significant end
returns.
PILL will utilise its state-of-the-art technology platform to assess potential new drug compounds (collected from animal venom).
Its drug discovery process results in a significant reduction in the discovery timeline and at substantial cost advantage relative to the traditional drug discovery process.
Timeline
Analytical work: which will include mass spectrometry proteome mapping to catalogue the peptides from venom Q1-2, 2016.
Bioinformatics: utilising PILL's proprietary software algorithm to predict the function and activities of the peptides Q3, 2016.
Potential Lead testing: Synthesise of selected peptides for testing using different assays to validate the predicated function and activities Q4, 2016.
The best molecules will then enter pre-clinical development and commence the pathway towards clinical testing and potentially, eventual, commercialisation.
Analysis
The key advantage of PILL's technology platform is that it allows the company to quickly and accurately (means fewer samples to start with) and cost effectively assess potential new drug candidates in a matter of months.
This is opposed to an extended number of years used in the traditional screening process to discover new drugs.
PILL therefore has the ability to repeat the process multiple times while traditional drug discovery would still be undertaking its first program.
This applies to all of PILL's three business areas – and in this way, its technology platform is truly ‘disruptive’ and ground breaking.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.